Regulatory Approvals - Invivyd, Inc. received emergency use authorization (EUA) from the FDA for PEMGARDA® (pemivibart) on March 22, 2024, for pre-exposure prophylaxis of COVID-19 in adults and adolescents [171]. - The company received Emergency Use Authorization (EUA) from the FDA for PEMGARDA on March 22, 2024, which is expected to support revenue generation [196]. Financial Performance - The company reported a net loss of $41.4 million for the nine months ended September 30, 2025, with an accumulated deficit of $943.4 million as of the same date [183]. - The net loss for the three months ended September 30, 2025, was $10.5 million, a decrease of $50.3 million from a net loss of $60.7 million in the same period of 2024 [204]. - Total revenue for the nine months ended September 30, 2025, was $36.2 million, compared to $11.6 million for the same period in 2024, reflecting an increase of $24.6 million [215]. - The company reported a net loss of $41.4 million for the nine months ended September 30, 2025, compared to a net loss of $151.5 million for the same period in 2024, a decrease of $110.1 million [212]. - For the nine months ended September 30, 2025, the company reported a net cash used in operating activities of $42.7 million, compared to $132.9 million for the same period in 2024 [234]. Research and Development - The Phase 1/2 clinical trial for VYD2311, a next-generation monoclonal antibody candidate for COVID-19, began in September 2024, with positive safety and pharmacokinetics data announced in June 2025 [172]. - The DECLARATION clinical trial, a pivotal Phase 3 trial for VYD2311, is expected to begin around the end of 2025, with top-line data anticipated in mid-2026 [174]. - Invivyd, Inc. aims to develop monoclonal antibodies for serious viral diseases, starting with COVID-19 and potentially expanding to other high-need indications [176]. - The company has engaged in active SARS-CoV-2 variant monitoring, reporting continued neutralizing activity of PEMGARDA against various variants [178]. - The SPEAR Study Group was formed in July 2025 to evaluate the effects of broadly neutralizing anti-SARS-CoV-2 monoclonal antibody therapy in patients suffering from Long COVID or Post-Vaccination Syndrome [175]. - The company plans to continue the commercialization of PEMGARDA and advance the development of VYD2311, along with conducting clinical trials for its product candidates [186]. - The company has initiated discovery efforts to expand its pipeline beyond SARS-CoV-2, targeting potential new indications such as respiratory syncytial virus and measles [191]. - Research and development expenses significantly decreased to $8.0 million in Q3 2025 from $57.9 million in Q3 2024, a reduction of $49.8 million [204]. - Research and development expenses for the nine months ended September 30, 2025, were $28.3 million, down from $119.3 million in 2024, a decrease of $91.0 million [219]. Expenses and Costs - Cost of product revenue was $1.1 million for the three months ended September 30, 2025, up from $0.8 million in 2024, resulting in a $0.3 million increase attributed to higher PEMGARDA sales [206]. - Selling, general and administrative expenses rose to $15.0 million in Q3 2025, compared to $13.0 million in Q3 2024, an increase of $2.1 million [204]. - The cost of product revenue was $2.6 million for the nine months ended September 30, 2025, compared to $0.9 million in 2024, an increase of $1.7 million [216]. Financing and Capital - Invivyd, Inc. has raised a total of $464.7 million from preferred stock sales, $327.5 million from its IPO, and $43.8 million from common stock sales under a Sales Agreement [182]. - The company had cash and cash equivalents of $85.0 million as of September 30, 2025 [223]. - The company financed operations primarily with net proceeds of $464.7 million from sales of preferred stock and $327.5 million from its IPO in August 2021 [222]. - The company generated $58.5 million from financing activities during the nine months ended September 30, 2025, compared to $39.3 million in the same period in 2024 [239]. - In October 2025, the company sold 18,655,402 shares at an average price of $1.60 per share, generating $28.9 million in proceeds [229]. - The company completed an underwritten public offering in August 2025, issuing 89,234,480 shares at $0.52 per share, raising approximately $53.5 million in net proceeds [231]. - The company entered into a Loan Agreement for a senior secured term loan facility of up to $30 million, with specific drawdown conditions based on revenue milestones [232]. Going Concern and Future Plans - The company has substantial doubt about its ability to continue as a going concern beyond one year from the issuance date of its financial statements, based on current operating plans [187]. - The company plans to finance operations through a combination of revenue contributions, equity offerings, and debt financing, which may dilute existing stockholders' interests [243]. - The company is committed to advancing the REVOLUTION clinical program for VYD2311 and other product candidates, impacting future funding requirements [241]. Compliance and Reporting - The company is exempt from compliance with the auditor attestation requirement in the assessment of internal control over financial reporting [251]. - The company has reduced disclosure obligations regarding executive compensation [251]. - The company is exempt from holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved [251]. - The company is exempt from compliance with the Public Company Accounting Oversight Board requirements regarding the communication of critical audit matters in the auditor's report on financial statements [251]. - The company qualifies as a smaller reporting company and is not required to provide certain market risk disclosures [252].

Product Development - Cytisinicline is an investigational product candidate aimed at treating nicotine dependence, with a PDUFA targeted action date of June 20, 2026, for its NDA submission [131]. - The FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation in 2024, expediting its development process [129]. - The ORCA-OL trial, which evaluated long-term safety exposure of cytisinicline, enrolled 479 subjects and was completed in September 2025 [140]. - The company plans to commence commercial sales of cytisinicline in the U.S. in the second half of 2026, utilizing AI tools for targeted marketing [133]. Financial Performance - The company reported a net loss of $40.0 million for the nine months ended September 30, 2025, with an accumulated deficit of $245.6 million [134]. - The company has incurred operating losses in each year since inception and has no products approved for commercial sale to date [134]. - The company expects to incur substantial additional losses in the future as it continues its operations [157]. - The company has not generated any revenue from product sales to date and may not do so in the near future [158]. Expenses and Cash Flow - Research and development expenses for the three months ended September 30, 2025, decreased to $5.3 million from $7.6 million in the same period of 2024, while expenses for the nine months increased to $19.1 million from $15.5 million [151]. - General and administrative expenses increased to $9.4 million and $21.0 million for the three and nine months ended September 30, 2025, respectively, compared to $4.9 million and $11.4 million for the same periods in 2024, primarily due to higher commercial launch preparation and employee costs [152]. - Total interest income decreased to $0.6 million and $1.1 million for the three and nine months ended September 30, 2025, respectively, down from $0.7 million and $1.9 million in the same periods in 2024, attributed to lower average cash balances and interest rates [153]. - Total interest expense decreased to $0.2 million and $0.6 million for the three and nine months ended September 30, 2025, respectively, compared to $0.4 million and $2.0 million for the same periods in 2024, due to a lower principal balance on the New Convertible Term Loan [154]. Cash and Securities - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $48.1 million, with a positive working capital balance of $40.3 million [134]. - As of September 30, 2025, the company had $50.0 million available under the Open Market Sale Agreement with Jefferies LLC [180]. - Net cash used in operating activities was $31.5 million for the nine months ended September 30, 2025, an increase from $20.6 million for the same period in 2024, primarily due to higher R&D expenses [186]. - Net cash provided by financing activities for the nine months ended September 30, 2025 was $45.3 million, compared to $47.8 million for the same period in 2024 [187]. - Net cash provided by investing activities for the nine months ended September 30, 2025 was $5.4 million, a significant improvement from $33.3 million used in the same period in 2024 [188]. Stock Offerings - In February 2024, the company sold 13,086,151 shares of common stock at a price of $4.585 per share in a registered direct offering [176]. - Concurrently, the company issued unregistered warrants to purchase up to 13,086,151 shares of common stock at an exercise price of $4.906 per share [177]. - The registered direct offering raised total gross proceeds of approximately $60.0 million, with net proceeds of approximately $56.1 million after deducting fees and expenses [178]. - The June 2025 public offering of 15,000,000 shares and accompanying warrants raised total gross proceeds of approximately $45.0 million, resulting in net proceeds of approximately $41.2 million after underwriting discounts and expenses [185]. - The exercises of the Underwriters' option raised gross proceeds of $4.3 million, with net proceeds of approximately $4.0 million after underwriting discounts [185]. Debt and Financing - The New Convertible Term Loan has an original principal amount of $10.0 million, with an additional $5.0 million available upon certain conditions, maturing on December 1, 2027 [166][168]. - The increase in cash used in operations in 2025 was attributed to the ORCA-OL open-label safety trial initiated in May 2024 [186]. Accounting Standards - No new accounting standards were adopted in 2025, as noted in the company's financial statements [192].

Revenue Performance - Annual Revenue Run-Rate (ARR) as of September 30, 2025, is $355.716 million, up from $354.608 million in June 2025, reflecting a steady growth trend [164]. - Subscription Annual Revenue Run-Rate (Subscription ARR) reached $268.617 million as of September 30, 2025, compared to $267.951 million in June 2025, indicating consistent revenue generation from subscriptions [164]. - Total revenue for the three months ended September 30, 2025, was $86,029,000, a 2.8% increase from $83,710,000 for the same period in 2024 [186]. - Subscription solutions revenue for the three months ended September 30, 2025, was $64,703,000, up 3.0% from $62,826,000 in 2024 [186]. - Partner and services revenue for the three months ended September 30, 2025, was $21,326,000, reflecting a 2.1% increase from $20,884,000 in 2024 [186]. - Total revenue for the nine months ended September 30, 2025, reached $252,832,000, a 2.8% increase compared to $245,899,000 in 2024 [186]. - Subscription solutions revenue for the nine months ended September 30, 2025, was $190,473,000, a 2.6% increase from $185,582,000 in 2024 [186]. - Partner and services revenue for the nine months ended September 30, 2025, was $62,359,000, up 3.4% from $60,317,000 in 2024 [186]. Customer Metrics - The number of Enterprise Accounts decreased slightly to 5,751 as of September 30, 2025, from 5,803 in June 2025, showing a minor decline in enterprise customer base [164]. - ARR attributable to Enterprise Accounts is $269.179 million, representing 76% of total ARR as of September 30, 2025, consistent with the previous quarter [164]. - Average Revenue Per Account (ARPA) increased to $46,806 as of September 30, 2025, up from $46,403 in June 2025, indicating improved revenue efficiency per account [164]. - Net revenue retention (NRR) for enterprise accounts was 99% for the year ended December 31, 2024, and 100% for 2023, indicating stable revenue maintenance [165]. Operational Efficiency - Gross profit for the three months ended September 30, 2025, was $67,434,000, compared to $63,847,000 in 2024 [184]. - Loss from operations for the three months ended September 30, 2025, was $(435,000), an improvement from $(19,217,000) in 2024 [184]. - Net loss for the three months ended September 30, 2025, was $(2,243,000), compared to $(6,993,000) in 2024, indicating reduced losses [184]. - Cost of revenue for the three months ended September 30, 2025, decreased by $1,268,000 (6.4%) compared to the same period in 2024, while gross profit increased by $3,587,000 (5.6%) with a gross margin of 78.4% [188][192]. - For the nine months ended September 30, 2025, cost of revenue decreased by $4,795,000 (8.3%), and gross profit increased by $11,728,000 (6.2%) with a gross margin of 78.9% [189][192]. - Operating expenses for the three months ended September 30, 2025, totaled $67,869,000, a decrease of $15,195,000 (18.3%) compared to the same period in 2024 [192]. Expense Management - Sales and marketing expenses for the three months ended September 30, 2025, increased by $3,141,000 (9.5%) to $36,281,000, primarily due to reclassification of expenses from cost of revenue [192][193]. - Research and development expenses decreased by $3,377,000 (16.2%) for the three months ended September 30, 2025, totaling $17,464,000, mainly due to reduced salaries and share-based compensation [192][196]. - General and administrative expenses decreased by $4,294,000 (26.1%) for the three months ended September 30, 2025, totaling $12,141,000, driven by lower bad debt and professional services costs [192][200]. Cash Flow and Financing - Net cash provided by operating activities for Q3 2025 was $10.6 million, a 90% increase from $5.6 million in Q3 2024 [214]. - For the nine months ended September 30, 2025, net cash provided by operating activities was $24.5 million, up 76% from $13.9 million in the same period of 2024 [215]. - Net cash used in investing activities for Q3 2025 was $(6.8) million, compared to $9.3 million in Q3 2024, primarily due to the purchase of marketable securities of $44.3 million [216]. - For the nine months ended September 30, 2025, net cash used in investing activities was $(10.7) million, a significant decrease from $62.6 million in the same period of 2024 [217]. - Net cash used in financing activities for Q3 2025 was $0.1 million, a drastic reduction from $112.1 million in Q3 2024, mainly due to lower repayments of convertible notes [218]. - For the nine months ended September 30, 2025, net cash used in financing activities was $53.1 million, down from $112.4 million in the same period of 2024 [219]. Financial Position - As of September 30, 2025, the company had $51.1 million in cash and cash equivalents, an increase of $14.1 million from $37.0 million as of September 30, 2024 [1]. - The marketable securities balance decreased to $92.1 million as of September 30, 2025, from $133.0 million in 2024 [1]. - The company believes existing cash and cash equivalents will be sufficient to meet working capital and capital expenditure needs for at least the next twelve months [223]. - The company issued $150.0 million in 2028 Convertible Notes with a 7.50% interest rate, maturing on October 1, 2028 [226]. - The company repurchased approximately $59.1 million of its 2026 Convertible Notes for about $54.4 million in cash, resulting in a net gain of approximately $3.9 million [235]. - As of September 30, 2025, approximately $4.0 million principal amount of 2026 Convertible Notes remain outstanding [235]. - An immediate increase or decrease in interest rates of 100 basis points could result in a $1.0 million market value reduction or increase [240]. Risk Management - All revenue and most expenses for the three months ended September 30, 2025, were transacted in U.S. dollars, minimizing foreign currency exchange risk [242]. - The company currently does not hedge foreign currency exposure but may consider using derivative financial instruments in the future [244]. - The company has not experienced any losses on deposits of cash and cash equivalents, indicating effective credit risk management [245]. - The company maintains its cash and cash equivalents in high credit quality securities to mitigate credit risk [245]. - There have been no material changes to critical accounting policies and estimates compared to previous reports [238]. - The company has no off-balance sheet arrangements as of September 30, 2025 [236]. Strategic Initiatives - The company completed a strategic rebranding initiative, unifying its core products under the single brand identity "Commerce," aimed at enhancing operational cohesion and scalability [144]. - The launch of a new branded payments offering is planned for fiscal year 2026, targeting small and medium-sized customers to improve monetization and customer retention [156]. - The company is focusing on expanding its presence in both B2B and B2C markets, with product enhancements aimed at meeting the needs of enterprise B2B businesses and underserved B2C verticals [150][151]. - AI integration is a core component of the company's strategy, enhancing product discoverability and optimizing pricing to improve merchant performance [149]. - The company is closely monitoring macroeconomic factors, including trade policies and tariffs, to mitigate potential impacts on its international customer base [158].

FOR IMMEDIATE ISSUE STAGWELL INC. (NASDAQ: STGW) REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 YTD Increase in Cash Flow from Operations of $100 million Over Prior Year Period Announced a Groundbreaking Partnership with Palantir Q3 YoY Revenue Growth of 4%, Q3 YoY Net Revenue Growth of 6% Q3 YoY Net Revenue Growth excluding Advocacy of 10%, Digital Transformation Net Revenue Growth of 12%, Marketing Services Net Revenue Growth of 9% Q3 Net Income Attributable to Stagwell Inc. Common ...

Exhibit 99.1 Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate CLYM116 Phase 1 tri ...

Exhibit 99.1 Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate CLYM116 Phase 1 tri ...

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update Third Quarter 2025 Financial Results Total revenue for the quarter ended September 30, 2025 was $14.3 million, an increase of $0.8 million, or 6%, compared to total revenue of $13.5 million for the quarter ended September 30, 2024. The increase in the third quarter of 2025 was primarily due to increased procedure volume. Worldwide procedure volume increased by approximately 11% in the third quarter of 2025 as compared to 2024. During th ...

BUSINESS HIGHLIGHTS RAP-219 Lead Program Focal Onset Seizures (FOS) Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update BOSTON and SAN DIEGO, November 6, 2025 -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the third quarter ending Sep ...

Financial Performance - The company has not generated any revenue from product sales since its inception and does not expect to do so in the near future [92]. - The company has a history of significant operating losses and negative cash flows from operations since its inception [87]. - The net loss for Q3 2025 was $50.610 million, compared to a net loss of $40.560 million in Q3 2024, reflecting an increase of $10.050 million (24.8%) [100]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $137.641 million, compared to $108.677 million in the same period of 2024, an increase of $28.964 million (26.7%) [111]. Cash and Investments - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $332.6 million, with an accumulated deficit of $537.4 million [87]. - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $332.6 million, with long-term investments and interest receivable of $142.9 million [106]. - The company has an at-the-market equity offering program allowing for the sale of up to $125.0 million in common stock, with $85.6 million remaining as of September 30, 2025 [110]. Research and Development - Research and development expenses increased by $6.5 million (18.3%) in Q3 2025 compared to Q3 2024, totaling $41.968 million, driven by clinical development costs and additional headcount [100][101]. - For the nine months ended September 30, 2025, research and development expenses rose by $42.0 million (41.0%) to $144.457 million, primarily due to a one-time upfront licensing fee of $20.0 million for velinotamig [101]. - The company is evaluating CLN-049 in an ongoing Phase 1 clinical trial for relapsed/refractory acute myeloid leukemia, with updated results expected at the 2025 ASH Annual Meeting [86]. - The company plans to share initial safety and B cell depletion data for CLN-978 in systemic lupus erythematosus and rheumatoid arthritis in the first half of 2026 [78]. - The Phase 2b portion of the REZILIENT1 trial for zipalertinib met its primary endpoint, and Taiho plans to initiate a rolling submission of a new drug application by the end of 2025 [78]. Licensing and Collaborations - The company entered into a license agreement with Genrix for velinotamig, paying an upfront fee of $20.0 million in June 2025 [88]. - The company entered into a licensing agreement with Genrix in June 2025, paying an upfront fee of $20.0 million for the exclusive rights to develop and commercialize velinotamig [108]. - The company has payment obligations contingent upon future events under various license and collaboration agreements, including milestone and royalty payments [122]. Risks and Future Funding - The company is subject to risks common to early-stage biotechnology companies, including reliance on third parties and the need for additional capital to fund operations [89]. - Future funding requirements may increase significantly due to ongoing research, clinical trials, and potential acquisitions to expand the product pipeline [119]. - The company expects to finance cash needs through equity offerings, debt financings, and collaborations, which may dilute current ownership interests [121]. Operating Expenses - Total operating expenses for Q3 2025 were $55.595 million, up $6.740 million (13.8%) from $48.855 million in Q3 2024 [100]. Intellectual Property - The company has a controlling interest in the worldwide intellectual property rights for CLN-619 (99%), CLN-049 (98%), and CLN-617 (96%) as of September 30, 2025 [83]. Accounting Policies - There have been no material changes to the company's critical accounting policies since the 2024 10-K [125]. - Recently issued and adopted accounting pronouncements that may impact financial position are disclosed in the quarterly report [126]. - The company is electing scaled disclosure requirements available to smaller reporting companies regarding market risk [127].

Bankruptcy and Financial Restructuring - WW International, Inc. emerged from Chapter 11 bankruptcy on June 24, 2025, discharging approximately $1,116.0 million in outstanding liabilities[172][175]. - The company completed a prepackaged bankruptcy filing under Chapter 11 to restructure approximately $1,116.0 million in liabilities and reduce ongoing interest payments[254]. - Fresh start accounting was applied post-emergence, resulting in separate financial statement presentations for Successor and Predecessor periods[176]. - The company executed a new senior secured credit agreement providing for a term loan of $465.0 million, maturing on June 24, 2030, to refinance first lien claims and provide working capital[175]. - As of September 30, 2025, the company had total outstanding debt of $465.5 million under the New Term Loan Facility[294]. Financial Performance - Revenues for the three months ended September 30, 2025, were $172.1 million, a decrease of 10.4% compared to $192.9 million for the same period in 2024[197]. - Gross profit was $124.1 million for the three months ended September 30, 2025, down from $129.5 million in 2024, with a gross margin of 72.1%, up from 67.1%[197][206][207]. - Net loss for the three months ended September 30, 2025, was $57.5 million, compared to a net loss of $46.2 million for the same period in 2024[219]. - Total revenues for the Successor Period from June 25, 2025, to September 30, 2025, were $184.3 million, a decline from $363.6 million in the Predecessor Period[230]. - Gross profit for the Successor Period was $133.0 million, with a gross margin of 72.2%[224]. - Operating income for the Successor Period was $10.6 million, with an operating income margin of 5.8%[224]. - The company reported cash and cash equivalents of $170.1 million as of September 30, 2025[295]. - Net cash provided by operating activities was $8.4 million for the period from June 25, 2025, through September 30, 2025, compared to net cash used of $34.4 million for the prior period[261]. Tax and Regulatory Impacts - The company anticipates a material impact on its annual estimated effective tax rate for 2025 due to the One Big Beautiful Bill Act signed into law on July 4, 2025[177]. - The effective tax rate was (1,219.5%) for the three months ended September 30, 2025, compared to 37.2% for the same period in 2024[214]. - The effective tax rate for the Successor Period included a provision for income taxes of $52.6 million[224]. - The company will continue to assess the impact of the One Big Beautiful Bill Act on its financial statements for fiscal year 2026 and beyond[177]. Subscriber Metrics and Revenue Streams - Behavioral Subscription Revenues decreased by 15.7% in nominal currency and 17.1% in constant currency compared to Q3 2024[221]. - Clinical Subscription Revenues increased by 35.3% in both nominal and constant currency compared to Q3 2024[221]. - The number of total subscribers decreased by 17.4% year-over-year, with Behavioral subscribers down by 19.0% and Clinical subscribers up by 56.5%[221]. - Subscription revenues for the combined first nine months of fiscal 2025 totaled $544.2 million, a decrease of 8.6% compared to $595.3 million in the same period of fiscal 2024[252]. - The number of total subscribers decreased by 12.2% to 2,986.4 thousand in fiscal 2025 from 3,666.7 thousand in fiscal 2024[252]. - Clinical subscription revenues increased by 46.2% to $84.1 million in fiscal 2025, up from $57.5 million in fiscal 2024[252]. Expenses and Cost Management - Marketing expenses increased to $48.4 million for the three months ended September 30, 2025, compared to $44.4 million in 2024, primarily due to higher online advertising spend[208]. - Cost of revenues decreased to $48.0 million for the three months ended September 30, 2025, from $63.4 million in 2024, driven by actions to reduce fixed costs[205]. - Total depreciation and amortization expenses increased to $25.5 million for the three months ended September 30, 2025, compared to $9.2 million in 2024[201]. - Marketing expenses decreased to $51.2 million for the period from June 25, 2025 through September 30, 2025, compared to $110.9 million in the previous period[234]. - Product development expenses were $8.2 million for the period from June 25, 2025 through September 30, 2025, down from $25.3 million in the prior period[235]. - Selling, general and administrative expenses were $63.0 million for the period from June 25, 2025 through September 30, 2025, compared to $78.5 million in the previous period[236]. Shareholder and Stock Information - The company distributed 10 million shares of Common Stock to holders of prepetition claims and common stock upon emergence from bankruptcy[175]. - The company’s common stock was relisted for trading on Nasdaq on July 3, 2025, after emerging from Chapter 11 bankruptcy[300]. - The share repurchase program authorized by the Board allows for up to $250.0 million in common stock repurchases, with $208.9 million remaining unutilized as of September 30, 2025[274]. - The company does not currently pay dividends and has no plans to do so in the foreseeable future, with future determinations at the discretion of the Board of Directors[273]. - The company’s ability to engage in share repurchases is uncertain and subject to the discretion of its Board of Directors[297]. Risks and Future Outlook - The company faces risks related to regulatory scrutiny of its compounded medications, which could adversely affect its reputation and business[303]. - The company is subject to various legislative and regulatory restrictions that govern its advertising, marketing, and operations[304]. - The company may face increased subscription terminations due to new regulations affecting subscription services[305]. - The business is seasonal, with the highest level of member recruitment typically occurring in the first quarter of the year[280]. - The company has not updated the financial projections filed during the Chapter 11 Cases, which may not materialize as anticipated[292]. - The company experienced a significant reduction in variable rate debt following its Chapter 11 financial reorganization, with a hypothetical 125 basis point increase in interest rates potentially increasing annual interest expense by approximately $5.8 million[285].